Oncology Resource Group (ONCrg) is an accomplished team of competitive intelligence professionals with strong scientific, clinical, and commercial proficiencies. Our analysts cultivate their unmatched expertise through continuous study of solid tumors, hematologic malignancies, and immuno-oncology to deliver unique, year-round competitive intelligence. ONCrg’s medical congress, competitive landscape, and surveillance reports provide unparalleled depth, breadth, and insight in each of our practice areas.
Sarah Lockhead, Ph.D.
Therapy Area Manager
Sarah received her Ph.D. in Chemical and Systems Biology from Stanford University and years spent in various drug development roles ranging from preclinical oncology portfolio development at Pfizer to drug repurposing at Stanford’s School of Medicine, enables her to provide clients with incisive analyses. Through the ONCrg Advisory services, you can contact Sarah directly for personalized answers to non-proprietary questions, targeted analyses, and custom insights in CLL.
Regina Cheung, Ph.D.
Therapy Area Manager
Regina received her Ph.D. in Immunology from Stanford University, where she helped develop novel technologies in transcriptional, proteomic, and cytokine secreting plasmacytoid dendritic cell analysis research. In addition to strong writing and presentation skills, Regina brings a data driven technical approach to problem solving gained from her undergrad degree at Caltech and master’s degree from MIT.
Pricing and More Information:
Call: 650-485-2626
Visit: www.onc-rg.com
Email: michael.reynolds@onc-rg.com
ONCrg Conference™ delivers unrivaled competitive intelligence from major congresses. ONCrg’s syndicated model covers the entire CLL landscape, but leaves room to add or drill down on your interests, so highly relevant reports are produced, including our expert opinions about the implications of new data on your pipeline.
Competitive Landscape Analysis
ONCrg Pipeline Strategies™ delivers cutting-edge profiles across the entire CLL competitive landscape, providing valuable analytics by class and treatment subset for new drugs in Phase I/II development and beyond. Reports are updated quarterly and written in two formats:
- a presentation format for higher level comparative analytics
- a corresponding compendium with additional detailed commentary from ONCrg experts
Monthly Surveillance Reports
ONCrg Sentinel™ provides vigilant monitoring of rapidly evolving scientific, clinical, and commercial activities in CLL. ONCrg experts identify and analyze events and deliver incisive commentaries to inform subscribers each month and prepare them to respond wisely to changing market conditions.
Expert Advisory Guidance
ONCrg Advisory™ is an open door to ask non-proprietary questions in CLL and your other subscription areas. Our experts utilize extensive resources and experience to provide extra guidance to inform clients’ key decisions.